Rifaximin suspension mix granule formulation
Patent Information
- Authority / Receiving Office
- CN · China
- Current Assignee / Owner
- 天津合益达生物医学技术有限公司
- Publication Date
- 2004-03-31
- Estimated Expiration
- Not applicable · inactive patent
Abstract
Description
technical field
[0001] The invention relates to the field of medicines, in particular to a rifaximin dry suspension granule capable of treating intestinal diseases. Background technique
[0002] Rifaximin is a new type of antibiotic widely used among rifamycin derivatives. It can be used to treat acute and chronic intestinal infections caused by Gram-positive bacteria and Gram-negative bacteria, and can be used as a therapeutic agent for hyperammonia. Auxiliary drugs. This drug has a broad antibacterial spectrum and has antibacterial effects on aerobic or anaerobic bacteria in the gastrointestinal tract. Its biggest feature is that it is neither absorbed by the intestinal tract nor purified by gastric juice, that is, this product is almost not absorbed systematically, and the drug concentration cannot be detected in the urine and tissues of patients after taking it, but is only excreted in its original form through the large intestine. Therefore, its toxic and side effects...